Antengene to Release Latest Results from the TORCH-2 Trial of mTORC1/2 Inhibitor ATG-008 in Poster Discussion at 2023 ASCO

SHANGHAI and HONG KONG,April 27,2023 -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK),a leading innovative,global biopharmaceutical company dedicated to discovering,developing and commercializing first-in-class and/or best-in-class medicines for cancer,today announced that the results of the Phase I/II TORCH-2 study will be presented as a poster discussion during the American Society for Clinical Oncology Annual Meeting (ASCO 2023),taking place from June 2nd to 6th at the McCormick Place Convention Center in Chicago,IL.

The TORCH-2 study is an open-label dose escalation and expansion study to evaluate ATG-008,an mTORC1/2 inhibitor,in combination with the anti-PD-L1 antibody,toripalimab,in patients with advanced solid tumors.

"We believe that combining ATG-008 with an immune checkpoint inhibitor could lead to more effective and durable control of tumors,because the mTOR signaling pathway plays multiple roles in immune cell biology. We look forward to sharing the results of the TORCH-2 study with the oncology community at ASCO 2023." said Dr. Amily Zhang,Antengene's Chief Medical Officer.

Details of the poster to be presented:

Title: A phase I/II study of the TORC1/2 inhibitor onatasertib combined with toripalimab in patients with advanced solid tumors

Abstract: 2526

Session: Developmental Therapeutics – Immunotherapy

Poster Session Display Date and Time: 8:00 AM - 11:00 AM,June 3,2023 (Central Time) / 9:00 PM,June 3 – 12:00 AM,June 4,2023 (Beijing Time)

Poster Board Number:368

Poster Discussion Session Date and Time:3:00 PM - 4:30 PM,2023 (Central Time) / 4:00 AM – 5:30 AM,2023 (Beijing Time)

About Antengene

Antengene Corporation Limited ("Antengene",SEHK: 6996.HK) is a leading commercial-stage R&D-driven global biopharmaceutical company focused on the discovery,development,manufacturing and commercialization of innovative first-in-class/best-in-class therapeutics for the treatment of hematologic malignancies and solid tumors,in realizing its vision of "Treating Patients Beyond Borders".

Since 2017,Antengene has built a pipeline of 9 oncology assets at various stages going from clinical to commercial,including 6 with global rights,and 3 with rights for the APAC region.To date,Antengene has obtained 28 investigational new drug (IND) approvals in the U.S. and Asia,and submitted 9 new drug applications (NDAs) in multiple Asia Pacific markets,with the NDA for XPOVIO® (selinexor) already approved in Mainland of China,Taiwan,China,South Korea,Singapore and Australia.

Forward-looking statements

The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law,we undertake no obligation to update or revise publicly any forward-looking statements,whether as a result of new information,future events or otherwise,after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article,statements of,or references to,our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement,see the section titled "Risk Factors" in our periodic reports filed with the Hong Kong Stock Exchange and the other risks and uncertainties described in the Company's Annual Report for year-end December 31,2021,and subsequent filings with the Hong Kong Stock Exchange.

For more information,please contact:

Investor Contacts:

Donald Lung

E-mail: Donald.Lung@antengene.com

Mobile: +86 18420672158

PR Contacts:

Peter Qian

E-mail: Peter.Qian@antengene.com

Mobile: +86 13062747000